Christopher Waddick
Director of Finance/CFO at CARDIOL THERAPEUTICS INC.
Net worth: 199 100 $ as of 30/03/2024
Profile
Christopher J.
Waddick is currently the Chief Financial Officer, Secretary & Director at Cardiol Therapeutics, Inc. since 2022.
He is also the President & Chief Financial Officer at Active Energy, Inc. since 2013 and the President at Nrj Consulting, Inc. since 2009.
Previously, he served as the Chief Financial & Executive Officer at Vasogen, Inc. from 2007 to 2009.
Mr. Waddick holds an MBA from York University and an undergraduate degree from Wilfrid Laurier University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 28/02/2024 | 110,000 ( 0.17% ) | 199 100 $ | 30/03/2024 |
Christopher Waddick active positions
| Companies | Position | Start |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Director of Finance/CFO | 15/08/2018 |
Active Energy, Inc.
 Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Director of Finance/CFO | 31/12/2012 |
| Nrj Consulting, Inc. | President | 31/10/2009 |
Former positions of Christopher Waddick
| Companies | Position | End |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Chief Executive Officer | - |
Training of Christopher Waddick
| York University | Masters Business Admin |
| Wilfrid Laurier University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Utilities |
| Cardiol Therapeutics, Inc. | |
| Nrj Consulting, Inc. |
- Stock Market
- Insiders
- Christopher Waddick
